"I love Accelerating global development with an Asian oncology platform - ASLAN Pharmaceuticals"

2022-05-06 16:53:48

ASLAN PharmaceuticalsPipelineOur TeamInvestor RelationsNews & PublicationsContactYou are now leaving our web site.The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.I understand Accelerating innovation in immunology ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Recent News 27 Apr 2022 ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update 6 Apr 2022 ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 28 Mar 2022 ASLAN Pharmaceuticals Announces Late-breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting 25 Mar 2022 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update View All News Our Pipeline EblasakimabPhase 1 FarudodstatPhase 1 Experienced Management TeamOur senior management team has an aggregate of over 70 years experience in global development and commercialisation.Learn more about our team Therapeutic AreasWe focus on atopic dermatitis, other immunology indications and autoimmune disease.Learn more about our drugs CompanyOur PipelineOur TeamInvestor RelationsNews & PublicationsContactTerms and Conditions DisclaimerCopies of this poster obtained through QR codes are for personal use only and may not be reproduced without written permission of the authorsAcceptDeclineDecline